Please provide your email address to receive an email when new articles are posted on . Compared with the original Cologuard test approved by the FDA in 2014, the company’s next-generation test uses ...
The Food and Drug Administration (FDA) has approved the Cologuard Plus™ test for colorectal cancer screening in adults aged 45 years and older who are at average risk for colorectal cancer. According ...
Colon cancer is the second-deadliest cancer in America. It's not deadly because it's particularly hard to treat or because oncologists are bad at spotting it. In large part, it's because people aren't ...
Colon cancer is the second-deadliest cancer in America. It's not deadly because it's particularly hard to treat or because oncologists are bad at spotting it. In large part, it's because people aren't ...
The trial was designed to evaluate the performance of next-generation Cologuard (multi-target stool DNA or mt-sDNA). Using colonoscopy as a reference method, the robust study design compared ...
The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results